All-Trans Retinoic Acid for Hemophagocytic Lymphohistiocytosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a medication called all-trans retinoic acid (ATRA) can help treat hemophagocytic lymphohistiocytosis (HLH), a rare condition where immune cells attack the body's own cells and tissues. You may be eligible if you have a new HLH diagnosis and have not yet received specific HLH treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Recently diagnosed with HLH (hemophagocytic lymphohistiocytosis) and not yet treated for it
- Have active signs of HLH, such as fever, low blood counts, high ferritin levels, enlarged spleen, or other HLH-related problems
- Able to take medication by mouth or through a feeding tube
- Not pregnant, not breastfeeding, and willing to use contraception if you can have children
- Expected to survive the study period based on doctor's judgment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, emapalumab and ruxolitinib, in people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. The goal is to find the safest and most effective doses of these medications.
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This study tests a drug called ATRA to help people with primary ITP (a condition where the body destroys its own platelets, causing bruising and bleeding) who haven't responded well to standard treatments. The goal is to see if ATRA can safely raise platelet counts in people who need better options.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Hear when a new Hemophagocytic Lymphohistiocytosis (HLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.